News · 18 November 2026

Zasocitinib more effective than deucravacitinib in phase 3 psoriasis trial

18 November 2026 · Vienna · Health · Science

Zasocitinib more effective than deucravacitinib in phase 3 psoriasis trial
Picture: Medscape · Medscape lead image · unknown

Zasocitinib outperformed deucravacitinib in a head-to-head phase three trial for moderate to severe plaque psoriasis across multiple efficacy measures. In 16 weeks, 36.5% of 301 patients on zasocitinib achieved complete skin clearance, compared with 13.9% of 303 patients on deucravacitinib. Safety profiles were similar with mostly mild or moderate adverse events and low discontinuation rates.

Where this came from. One outlet reported this. We read it, then wrote the sixty words above.

Also on 18 November 2026